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Summary The hypothalamic—pituitary—adrenal (HPA) axis is a psychoneuroendocrine regula-
tor of the stress response and immune system, and dysfunctions have been associated with
outcomes in several physical health conditions. Its end product, cortisol, is relevant to fatigue due
to its role in energy metabolism. The systematic review examined the relationship between
different markers of unstimulated salivary cortisol activity in everyday life in chronic fatigue
syndrome (CFS) and fatigue assessed in other clinical and general populations. Search terms for
the review related to salivary cortisol assessments, everyday life contexts, and fatigue. All
eligible studies (n = 19) were reviewed narratively in terms of associations between fatigue and
assessed cortisol markers, including the cortisol awakening response (CAR), circadian profile (CP)
output, and diurnal cortisol slope (DCS). Subset meta-analyses were conducted of case—control
CFS studies examining group differences in three cortisol outcomes: CAR output; CAR increase;
and CP output. Meta-analyses revealed an attenuation of the CAR increase within CFS compared to
controls (d = .34) but no statistically significant differences between groups for other markers.
In the narrative review, total cortisol output (CAR or CP) was rarely associated with fatigue in any
population; CAR increase and DCS were most relevant. Outcomes reflecting within-day change in
cortisol levels (CAR increase; DCS) may be the most relevant to fatigue experience, and future
research in this area should report at least one such marker. Results should be considered with
caution due to heterogeneity in one meta-analysis and the small number of studies.
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The repeated assessment of salivary cortisol has enabled the
examination of hypothalamic—pituitary—adrenal  (HPA) axis
activity and its relationship with various psychosocial and
somatic experiences in everyday life with high levels of
ecological validity (Kirschbaum and Hellhammer, 1989;
Schlotz, 2011). Fatigue is a relatively common somatic
experience, experienced by up to 40% of the general popu-
lation (Wessely et al., 1997; Ricci et al., 2007; van’t Leven
et al., 2010) and considered the primary motive for 6.5% of
general practitioner visits and a discreet symptom in 19%
(Cullen et al., 2002). Fatigue is prevalent in many clinical
populations (e.g., Barnes and Bruera, 2002; Sullivan and
Dworkin, 2003; Krupp et al., 2010), and is frequently
described as having a detrimental impact on daily living
(Hewlett et al., 2005; Lerdal et al., 2007). Chronic fatigue
syndrome (CFS) is thought to conceivably represent the
extreme end of a fatigue continuum (Pawlikowska et al.,
1994). CFS is characterized by profound and persistent
fatigue lasting at least six months, coexisting with several
other symptoms such as muscular pain and short-term mem-
ory loss (Fukuda et al., 1994). However, some have suggested
CFS may be qualitatively and quantitatively different to
chronic fatigue per se, including fatigue secondary to dis-
tinct conditions such as multiple sclerosis or cancer (Wes-
sely, 2001).
The relevance of hypocortisolism to bodily disorders
such as CFS has previously been hypothesized (Heim
et al., 2000; Fries et al., 2005). Cortisol secretory activity
(CSA) is relevant to fatigue due to cortisol’s regulatory role
in energy metabolism, the high prevalence of fatigue in
conditions characterized by low cortisol levels (such as
Addison’s disease), and the relative efficacy of glucocorti-
coid treatments in alleviating short-term fatigue (McKenzieet al., 1998; Cleare et al., 1999; Sapolsky et al., 2000;
Khani and Tayek, 2001). In an influential study of HPA axis
activity in CFS by Demitrack et al. (1991), significantly
reduced 24 h urinary free cortisol, attenuated evening
plasma cortisol levels, reduced cortisol responses to adre-
nocorticotropic hormone (ACTH) administration, and
blunted ACTH responses to oral corticotrophin releasing
hormone (CRH) were reported in CFS versus controls. Prior
to this, Poteliakhoff (1981) had also demonstrated atte-
nuated plasma cortisol levels in individuals experiencing
chronic fatigue.
Since these early findings, relevant studies have accumu-
lated and published reviews have generally described an
attenuation of CSA in CFS (Cleare, 2003; Tak et al., 2011;
Papadopoulos and Cleare, 2012). However, this is far from
unequivocal, and there are several studies observing no
attenuation of CSA or, indeed, raised CSA in CFS (Wood
et al., 1998; Inder et al., 2005; Papadopoulos et al.,
2009). As such, whether CSA contributes to the etiology of
CFS is currently unknown. In addition, despite its potential
relevance to fatigue experienced in other populations, no
review has yet examined the relationship between CSA and
fatigue other than in CFS.
The cortisol awakening response (CAR) describes a surge in
cortisol levels upon awakening (Wilhelm et al., 2007), and
has two components: (1) the total cortisol output within this
period and (2) the dynamic response, usually referring to the
change in cortisol output from waking to peak levels (Clow
et al., 2004). Typically, total cortisol output is estimated by
computing the area under the curve from baseline 0 (AUCG)
using constituent assessments, and the dynamic response by
the area under the curve from a baseline defined as cortisol
level at waking (AUCI) (Pruessner et al., 2003) or a variant of
cortisol peak-level minus waking-level calculation. A pre-
vious review of CAR studies detailed that each component
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factors (Chida and Steptoe, 2009).
The diurnal cortisol slope (DCS) models the declining
pattern of CSA throughout the rest of the day, following
the CAR (Adam and Kumari, 2009). An estimation of total
cortisol output may also be calculated for the complete
circadian rhythm (or profile) using AUCG or mean cortisol
levels. However, a review advised that circadian AUCG should
predominantly be used to complement other measures of CSA
as, although it provides ‘‘unique information’’ about average
levels of cortisol, it neglects diurnal variation (Adam and
Kumari, 2009, p. 1431).
Examining the relationship between fatigue and CSA in
real world contexts with high ecological validity is warranted
given the impact fatigue has on the quality of life of those
who experience it (Repping-Wuts et al., 2008). Laboratory
environments can confound cortisol measurements due to
the novelty stress of first-time laboratory or hospital visits, as
well as physiological reactivity induced by the venipuncture
procedure itself in serum sampling (Schlotz, 2011). Urinary
sampling for cortisol is sometimes utilized in research
designs, but offers only a summary index of cortisol produc-
tion over a period of time (Schlotz, 2011). When incorporat-
ing strategic salivary cortisol assessments, studies abiding by
research traditions such as ambulatory assessment (Ebner-
Priemer and Kubiak, 2010; Trull and Ebner-Priemer, 2013) or
ecological momentary assessment (Stone and Shiffman,
1994) can acquire frequent and fairly rapid repeated mea-
sures of circulating free cortisol. The present review exam-
ined studies of different CSA markers operationalized by
saliva sampling in everyday life and their respective relation-
ships with fatigue in (1) CFS; (2) other clinical groups; and (3)
nonclinical populations.
2. Method
2.1. Search strategy
Systematic searches were made using the MEDLINE (Ebsco);
PsycINFO (Ebsco); Embase (Ovid); Web of Science (ISI Web of
Knowledge); and CINAHL (Ebsco) electronic databases
(between database start and 1st June, 2012). Reference
lists of similar review articles were hand-searched for poten-
tially relevant articles. Search strings were created as fol-
lows: (1) ‘‘fatigue’’, (2) ‘‘saliva*’’ and ‘‘cortisol’’, and (3)
‘‘circadian’’ or ‘‘diurnal’’ or ‘‘basal’’ or ‘‘daily’’ or ‘‘every-
day’’ or ‘‘daytime’’ or ‘‘slope’’ or ‘‘profile’’ or ‘‘morning’’ or
‘‘awaken*’’ or ‘‘evening’’ or ‘‘waking’’ or ‘‘wake’’ (where *
indicates truncation). Conference proceedings, disserta-
tions, and theses were not included. No review protocol
was published.
2.2. Study selection and criteria for inclusion
Articles were included if they met the following criteria:
(1) adult population (18 years); (2) published in English;
(3) analyzing original data; (4) ambulatory design, featur-
ing salivary cortisol assessments on at least one occasion
per day (fixed-occasion if only one); and (5) fatigue mea-
sured as an outcome or predictor variable, using (i) an
established scale, defined as gaining at least partialinclusion in the Whitehead review of unidimensional and
multidimensional measures of fatigue (Whitehead, 2009);
(ii) momentary assessments; or (iii) a population with a
recognized diagnosis of CFS (meeting Fukuda et al. (1994)
or Sharpe et al. (1991) criteria). Exclusion criteria for this
review were: (1) studies of HPA axis reactivity to pharma-
cologic, physiologic, or psychosocial stimulation, unless
qualifying data was provided prior to stimulation; (2)
randomized controlled trials, unless providing qualifying
baseline data; (3) inclusion of pregnant women; (4) inclu-
sion of sleep-deprived or shift workers; and (5) inclusion of
participants taking steroidal medications at the time of the
study.
2.3. Data extraction
After removal of duplicate records, titles and abstracts were
screened for obvious departures from review criteria, fol-
lowed by full-text screening of those remaining. The follow-
ing data were extracted: (1) author; (2) year; (3) definition of
fatigue, if given; (4) study design (case/control, etc.); (5)
participant characteristics (population; number; age; gen-
der; criteria for inclusion/exclusion); (6) number and timing
of cortisol assessments; (7) number of sampling days; (8)
method of maximizing compliance, if any; (9) saliva sampling
procedure; (10) behavioral instructions around saliva sam-
pling; (11) cortisol assay used; (12) chosen fatigue measure;
(13) facets of fatigue experience measured (for example,
physical or mental fatigue components); (14) variables con-
trolled in the analyses; (15) mean/SD of cortisol assessments
and/or computations; (16) mean/SD of fatigue measures;
(17) statistical analysis used; (18) results and conclusions.
Where incomplete or unclear information was reported,
attempts were made to contact the study authors by email
for verification. Where salivary cortisol data was unavailable,
the study was excluded. Study screening and data extraction
was completed by DP.
2.4. Assessment of study quality
Study quality was assessed by a scale developed by the
authors, as no appropriate tool existed in the research area
focusing on the acknowledged methodological concerns in
studies of salivary cortisol assessment in everyday life
(Hansen et al., 2008; Adam and Kumari, 2009; Schlotz,
2011). Quality tools used in related systematic reviews
were examined, such as in reviews of studies of HPA axis
activity in functional somatic disorders (Tak et al., 2011)
and of CAR studies (Chida and Steptoe, 2009), and features
of both were incorporated where appropriate. As well as
discussions between the authors, we also consulted three
independent experts in the research area at different
stages of the formulation of the scale. Each expert was
emailed with a version of the scale and asked to comment
on each specific item and to identify any oversights on our
part.
The final scale items and scoring options are detailed in
Table 1. A maximum score of 16 was possible for each study.
For the purposes of this review, the study quality scale was
applied independently by two authors (DP and WS), with
discrepancies resolved by discussion.
Table 1 Scale to assess methodological quality of everyday life salivary cortisol studies.
(1) Is the population defined with inclusion and exclusion criteria?
 Medication use, disease status, psychiatric morbidity; all 3 stated (2)
 Medication use, disease status, psychiatric morbidity; 2 stated (1)
 None or one stated, or not clearly stated (0)
(2) Are the methods for salivary cortisol assessment clearly described and appropriate?
 Two or more assessment days, repeated assessments within days with assessment times reported, saliva sampling method,
storage conditions, type of assay performed; all 5 stated (2)
 Repeated assessments within days with assessment times reported, saliva sampling method, storage conditions, type of
assay performed; 3—4 stated (1)
 Less than 3 stated or not appropriate (0)
(3) Is adherence to the sampling protocol controlled?
 Electronic monitoring or prompting, with deviations from protocol observed and controlled, including the objectively
observed time of awakening (3)
 As above, but without objectively observing the time of awakening (2)
 Electronic prompting, but deviations from protocol not observed and controlled; OR self-reported sampling times, with
deviations observed and controlled (1)
 No appropriate controls, or not stated (0)
(4) If there are early-morning (before 1000 h) salivary measures within the design, were all requested at a time relative to the
actual waking time (i.e., upon awakening, or awakening plus 30 min, etc.) OR more than 60 min after awakening?
 Yes, or no pre-1000 h measure included (2)
 No, but awakening time assessed and statistically controlled (1)
 No, or not clearly reported (0)
(5) Were missing cortisol assessments dealt with appropriately in the analyses?
 No missing data; OR principleda missing data technique used when estimating parameters (3)
 Parameters based on non-complete but adequate data to provide reliable estimatesb (2)
 Ad hoca missing data technique used (1)
 No method of dealing with missingness reported, or inappropriate (0)
(6) Is the outcome cortisol measurement clearly presented (verbally, graphically or both) with appropriate units?
 Central tendencies, and measures of dispersion presented for each fixed time-point and all computed cortisol estimates
(e.g., AUC) (2)
 Central tendency and measures of dispersion presented for either fixed time-point or computed cortisol estimates (1)
 Outcome not clearly presented (0)
(7) Does the study provide appropriate control/adjustment for confounding variables in the relevant analysis? c
 Age, gender, socio-economic status, menstrual cycle,d body mass index, smoking, depression, medication,e physical exercise,
eating shortly before sampling saliva, stressor experience, 6—11 stated (in CAR studies, then also consider waking time,
brushing teeth during CAR measurement period, drinking anything other than water during CAR measurement period,
sampling day (weekend/weekday), 9—15 stated) (2)
 Age, gender, socio-economic status, menstrual cycle,d body mass index, smoking, depression, medication,e physical exercise,
eating shortly before sampling saliva, stressor experience, 3—5 stated (in CAR studies, +waking time, brushing teeth during
CAR measurement period, drinking anything other than water during CAR measurement period, sampling day (weekend/
weekday), 6—8 stated) (1)
 Age, gender, socio-economic status, menstrual cycle,d body mass index, smoking, depression, medication,e physical exercise,
eating shortly before sampling saliva, stressor experience, 0—2 stated (in CAR studies, +waking time, brushing teeth during
CAR measurement period, drinking anything other than water during CAR measurement period, sampling day (weekend/
weekday), 0—5 stated) (0)
a Principled missing data techniques refer to likelihood-based and Bayesian estimation methods, and multiple imputation. Ad hoc missing
data techniques refer to case deletion or single imputation methods.
b To be considered an adequate level of data, must have >2 completed assessments for daytime cortisol estimations and >1 assessment for
the CAR. Where cases were deleted due to insufficient completed assessments, a comparison of characteristics of included and excluded
cases should be made. Not meeting these criteria should result in a score of 0.
c Only score for analysis relevant to the review. If study includes any of the confounders as exclusion criteria in participant recruitment,
consider these controlled. If potential confounders are compared between groups (with or without explicit matching procedure) and no
difference found ( p > .05), consider that these variables have been controlled for if they are omitted from subsequent analyses. Person-
level, day-level, or assessment-level control and adjustment is acceptable.
d In male-only studies, menstrual cycle redundant and 6—10 (9—15) required for a score of 2. Requirements for 1 or 0 points unchanged.
e Medication includes hormone replacement therapy, contraceptives, steroids, psychotropic drugs, etc. Accept if study controls for one or
all of these.
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The heterogeneity of designs and populations between qua-
lifying studies led to a narrative review being conducted.
Three meta-analyses were also carried out within a subset of
studies which had cross-sectional CFS case—control designs.
These examined differences between CFS and control groups
for CAR total output (meta-analysis 1); CAR dynamic response
(meta-analysis 2); and circadian cortisol output (meta-ana-
lysis 3). It has been argued that where constituent study
characteristics are similar, meta-analysis represents the most
appropriate synthesis method even where the number of
studies is very small (Valentine et al., 2010).
Standardized mean differences (SMD) were calculated in
all cases using AUCG and AUCI computations, depending on
the aim. Cohen’s d was the preferred SMD measure due to a
tendency for group sizes to be quite different (McGrath,
2006). Where studies computed AUC on more than one
day, but did not compute between-day AUC mean and SDs,
the decision was made a priori to use only Day 1 data for the
meta-analyses. All cortisol values were converted to nmol/L
units beforehand, and SDs calculated from confidence inter-
vals where necessary. A random-effects model was consid-
ered most appropriate given it assumes varying effect sizes
between studies, and it permits inferences that generalize
beyond those studies included here (Field and Gillett, 2010).
Where appropriate, Cochrane’s Q and the I2 statistic were
calculated to check for heterogeneity between studies.
Where significant mean effect sizes were found, Rosenthal’s
Fail Safe N (FSN) (Rosenthal, 1979) was used to check for any
evidence of publication bias. Analyses were carried out using
Review Manager software (The Nordic Cochrane Centre, The
Cochrane Collaboration, Version 5.1, 2011), and bespoke
meta-analysis syntax to compute FSN (Field and Gillett,
2010) using SPSS (IBM SPSS Statistics, Version 20, 2011).
3. Results
3.1. Search and study selection
The study selection process is detailed in Fig. 1. Searches
revealed 514 potentially-relevant papers, and we identified
and removed 277 duplicate records of the same report. Fol-
lowing screening and application of selection criteria, data
from 19 papers was extracted. Of note, the studies by Nater
et al. (2008) and Heim et al. (2009) appeared to be relevant
multiple reports of the same study, but testing different
hypotheses. We were unable to verify duplicate samples with
the authors. We retained Nater et al. (2008) as this report
appeared to more closely match the purpose of this review.
Eight studies implementing cross-sectional case—control
designs in CFS were selected for the subset meta-analyses
(Strickland et al., 1998; Young et al., 1998; Gaab et al., 2002;
Roberts et al., 2004; Jerjes et al., 2005; Nater et al., 2008;
Papadopoulos et al., 2009; Rahman et al., 2011), and are
summarized in Table 2. Two studies qualified for meta-ana-
lysis 1 (Gaab et al., 2002; Nater et al., 2008), two for meta-
analysis 2 (Roberts et al., 2004; Nater et al., 2008), and three
for meta-analysis 3 (Young et al., 1998; Nater et al., 2008;
Papadopoulos et al., 2009). Other markers of CSA, such as
DCS, were discussed in the narrative review. Seven studies ofclinical populations other than CFS qualified (Dekkers et al.,
2000; Bower et al., 2005; McLean et al., 2005; Barroso et al.,
2006; Bay and Xie, 2009; Sudhaus et al., 2009; Gold et al.,
2011); see Table 3. Three nonclinical population studies were
also included (Lindeberg et al., 2008; Kumari et al., 2009; Eek
et al., 2012); see Table 4. For clarity, all saliva samples
provided upon awakening are henceforth referred to as
T0, T30 (30 min after awakening), and so on.
3.2. Study quality
Quality Scale item scores for each study are presented in the
supplementary material and the total score in the final
column of Tables 2—4. Respective study populations and
salivary cortisol assessments were generally well-defined
and reported within the studies reviewed. Several studies
failed to incorporate any method toward maximizing adher-
ence to the sampling design, and several potentially con-
founded data by ignoring actual waking time when requesting
early-morning samples. One potential source of bias appar-
ent in the majority of studies reviewed was the omission of
any analytical plan for dealing with missing assessments. The
median score for the Quality Scale was 7 out of 16, with
scores for CFS studies ranging from 3 to 11, and for other
populations from 4 to 14.
3.3. Chronic fatigue syndrome studies
Eight case—control studies were selected, incorporating 636
participants. All studies where fatigue severity was measured
revealed statistically significant differences in fatigue scores
between groups. One additional qualifying study did not
incorporate a control group and used a fatigue measure to
distinguish levels of fatigue within their CFS population
(Torres-Harding et al., 2008). Comorbid psychiatric disorders
were present within the CFS group in six out of the nine
studies included.
Three studies assessed the CAR (Gaab et al., 2002; Roberts
et al., 2004; Nater et al., 2008). In meta-analysis 1, across
both studies measuring CAR AUCG (Gaab et al., 2002; Nater
et al., 2008) (CFS n = 96, healthy control n = 131) the mean
between-group effect size was d = .27 (95% CI, .58, 1.12)
with no significant overall effect (Z = .62, p = .53). Fig. 2(i)
reflects this, showing that, although the study by Gaab et al.
(2002) showed a higher CAR AUCG in CFS, this was not
replicated in the study by Nater et al. (2008). However,
meta-analysis 1 likely reflected a heterogeneous sample of
studies (I2 = 83%; Cochran’s Q x2 = 6.06, p = .01).
In meta-analysis 2, which examined CAR AUCI, across both
studies (Roberts et al., 2004; Nater et al., 2008) (CFS n = 131,
healthy control n = 145) the mean between-group effect size
was d = .34 (95% CI, .58, .09) and revealed a significant
overall effect (Z = 2.72, p = .006, FSN = 4). Both studies indi-
vidually found a significant between-group difference for
AUCI (see Fig. 2(ii)) reflecting an attenuated cortisol response
to awakening in CFS from T0. Meta-analysis 2 did not reflect
heterogeneity (I2 = 0%; Cochran’s Q x2 = .21, p = .65).
Four studies examined group differences in the circadian
cortisol profile (Young et al., 1998; Gaab et al., 2002; Jerjes
et al., 2005; Papadopoulos et al., 2009). Three of these
(Young et al., 1998; Gaab et al., 2002; Papadopoulos
Figure 1 Flow chart of study screening and exclusion process. * indicates fatigue that was not assessed by a measure meeting full or
partial inclusion in Whitehead (2009) review.
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entered into meta-analysis 3. The remaining paper (Jerjes
et al., 2005) carried out cosinor rhythm analysis. Across all
three studies (CFS n = 61, healthy control n = 63) the mean
between-group effect size was d = 3.18 (95% CI, .38, 5.98),
reflecting a significant overall effect (Z = 2.23, p = .03).
Fig. 2(iii) depicts this. Heterogeneity was high (I2 = 97%;
Cochran’s Q x2 = 64.12, p < .001), and one study (Papado-
poulos et al., 2009) provided outlying results. The study by
Papadopoulos et al. (2009) was excluded in a subsequent
meta-analysis (Fig. 2(iv)) where heterogeneity between stu-
dies was rejected (I2 = 0%; Cochran’s Q x2 = .54, p = .46). The
remaining studies (CFS n = 43, healthy controls n = 43)
reflected a mean effect size of d = .01 (95% CI, .43, .42)
with no significant overall effect (Z = .03, p = .98).
Only one of the CFS case—control studies examined corti-
sol variability within the whole day, using cosinor analysis to
perform individual and population mean computations asdetailed in the relevant column of Table 2 (Jerjes et al.,
2005). MESOR (midline estimate statistic of rhythm), defined
as the rhythm-adjusted mean cortisol, was shown to be
significantly lower in the CFS group than the control group.
Amplitude, which was defined as half the difference between
daytime cortisol peak and nadir, was also lower in CFS than
healthy controls.
Examination of fixed time-based group comparisons in the
case—control studies were mixed, with one study revealing
lower CSA in the CFS group at every assessment (T0, 0900 h,
1200 h, 1500 h, 1800 h) except 2100 h, where there was no
difference (Jerjes et al., 2005). Another study observed
lower levels of CSA in the CFS group only at 2100 h (and
not at 1100 h: the only other assessment) (Strickland et al.,
1998). In the remaining study performing such comparisons,
no statistically significant differences were observed
between groups at any assessment (T30, 1200 h, 1800 h,
2200 h) (Rahman et al., 2011).
Table 2 Characteristics of CFS case—control and cross-sectional studies.
Study Design Sample: N (% female),
mean age (SD)
Psychiatric
comorbidity
Saliva sampling
protocol
Basal cortisol
computations
Main findings Quality
scorea
(16)
Gaab et al.
(2002)
Case—control,
cross-sectional
CFS: 21 (52), 36.0
years (4.5); control:
21 (52), 35.2 years
(4.5).
1 CFS had current
episode of major
depression (MD); 7
CFS history of MD; 4
CFS history of
anxiety disorder.
Days: 2;
assessments: 9 (T0,
T15, T30, T45, T60,
0800 h, 1100 h,
1500 h, 2000 h).
CAR (AUCG);
circadian profile
(AUCG).
No difference between groups
on any basal cortisol measure.
Graphical representation does
seem to suggest flatter CARs in
CFS than controls, although not
statistically tested.
8
Jerjes et al.
(2005)
Case—control,
cross-sectional
CFS: 15 (53), 35 years
(7.9); control: 20 (50),
33 years (11.3).
Individuals with
current major
depression or
anxiety disorders
excluded.
Days: 1;
assessments: 6 (T0
(0600 h), 0900 h,
1200 h, 1500 h,
1800 h, 2100 h).
Circadian profile
(‘‘goodness of fit’’
to cosinor curve,
midline estimate
statistic of rhythm
(MESOR),
amplitude,
acrophase); fixed
time point.
Evidence for reduced basal
cortisol secretory activity in CFS
compared to controls, in terms
of both MESOR and amplitude
(half the cortisol peak minus
nadir).
Lower cortisol levels observed
at all time points, except 2100.
6
Nater et al.
(2008)
Case—control,
cross-sectional
CFS: 75 (77), 43.9
years (SD not given);
control: 110 (75), 44.8
years (SD not given).
21.3% of CFS group
fulfilled diagnostic
criteria for MD.
Days: 1;
assessments: 3 (T0,
T30, T60).
CAR (AUCG, AUCI,
slope, peak-
waking).
Evidence that CFS may be
associated with an attenuated
CAR, but effect only present in
women (overall associations
shown actually represent that
shown in females; no association
apparent in men).
AUCI, slope, and peak minus
waking levels all attenuated in
female participants.
11
Papadopoulos
et al. (2009)
Case—control,
cross-sectional
CFS: 18 (56), 39.1
years (8.2); control:
20 (65), 39.5 years
(11.4).
9 CFS with
comorbid
depression.
Days: 1b;
assessments: 4
(0800 h, 1200 h,
1600 h, 2000 h).
Circadian profile
(AUCG).
Basal cortisol output
significantly higher in CFS
compared to controls (CFS with
and without comorbid
depression both raised
compared to controls).
6
Rahman
et al. (2011)
Case—control,
cross-sectional
CFS: 15 (87), 32.5
years (11.1); control:
15 (67), 35.6 years
(13.9).
MD and psychosis
excluded.
Days: 1;
assessments: 4
(T30 (to have
occurred 0600—
0800 h), 1200 h,
1800 h, 2200 h).
Fixed time points
only.
No difference at any time point. 11
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Table 2 (Continued )
Study Design Sample: N (% female),
mean age (SD)
Psychiatric
comorbidity
Saliva sampling
protocol
Basal cortisol
computations
Main findings Quality
scorea
(16)
Roberts
et al. (2004)
Case—control,
cross-sectional
CFS: 56 (63), 39.4
years (11.0); control:
35 (60), 34.9 years
(12.8).
22 CFS with
comorbid
depression.
Days: 1;
assessments: 5 (T0,
T10, T20, T30,
T60).
CAR (AUCI). Lower CAR in CFS group
compared to controls.
9
Strickland
et al. (1998)
Case—control,
cross-sectional
CFS: 14 (100), 36 years
(11); depressed: 26
(100), 34 (6); control:
131 (100), 34 years
(7).
10 CFS mild or
moderate
depressive
episodes.
Days: 2;
assessments: 2
(1100 h, 2100 h).
Fixed time points
(morning,
evening).
No difference in 1100 cortisol
between groups (trend for lower
cortisol in CFS).
CFS without comorbid
depression significantly lower
cortisol at 1100 than controls.
Cortisol lower for CFS at 2100
than both controls and
depressed group.
8
Torres-Harding
et al. (2008)
Cross-sectional CFS: 108 (83),
men = 39.6 (11.5);
women = 43.9 (11.4).
Not stated, but
individuals with
psychiatric
disorder and taking
antidepressants
clearly present
within sample.
Days: 1;
assessments: 5 (T0,
T45, 0900 h,
1600 h, 2100 h).
Circadian profile
(mean day cortisol,
slope, physician
classification of
profile as
‘‘normal’’ or
‘‘abnormal’’).
No relationship between level of
fatigue within CFS and mean
cortisol or diurnal slope.
Those with ‘‘abnormal’’ cortisol
profiles had higher fatigue
severity than those with
‘‘normal’’ profiles.
3
Young et al.
(1998)
Case—control,
cross-sectional
CFS: 22 (45), 39 years
(8.8); control: 22 (45),
38 years (8.0).
Current depressive
or anxiety disorder
excluded. 2 CFS
definite history of
MD, 10 CFS
probable history of
MD.
Days: 1;
assessments: 4
(0800 h, 1200 h,
1600 h, 2000 h).
Circadian profile
(AUCG).
No difference between groups. 6
a See quality scale items and respective scores in supplementary material for further information.
b Additional measurement day in study but was post-administration of dexamethasone.
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Table 3 Characteristics of clinical population studies.
Study Design Sample
population, N (%
female), mean age
(SD)a
Saliva sampling protocol Basal cortisol
computations
Fatigue measure Main findings Quality
scoreb
(16)
Barroso et al.
(2006)
Cross-sectional HIV-positive, 40
(28), 39.45 years
(SD not given).
Days: 1; assessments: 3
(0700 h, 1500 h, 2200 h).
None. Only visual slope
trends.
HIV-Related
Fatigue Scale.
An upwards cortisol slope
over the day (n = 5) had
highest levels of fatigue
(not empirically tested).
4
Bay and Xie
(2009)
Cross-sectional Mild-to-moderate
traumatic brain
injury, 75 (48),
mean age and SD
not reported.
Days: 1; assessments: 4
(0800 h, 1200 h, 1600 h,
2200 h).
Circadian profile (AUCG). Fatigue subscale of
the Profile of Mood
States.
AUCG did not predict
concurrent fatigue (it did
not contribute to their
regression model of
fatigue alongside other
covariates).
6
Bower et al.
(2005)
Cross-sectional Breast cancer
survivors, 29 (100),
fatigued = 58.2
years; not
fatigued = 61.8
years (SDs not
given).
Days: 2; assessments: 4;
(T0 (not while still in
bed), 1200 h, 1700 h,
2200 h).
Circadian profile (AUCG,
mean cortisol across
days, diurnal slope).
Fatigue subscale of
RAND SF-36.
Higher levels of fatigue
were assoc. with flatter
cortisol slopes, possibly
as a consequence of
reduced cortisol decline
in the evening.
8
Dekkers et al.
(2000)
Cross-sectional Rheumatoid
arthritis (recently
diagnosed), 25
(76), 55.2 years (SD
not given).
Days: 2; assessments: 9
(T0, T15, T30, T45,
1000 h, 1200 h, 1430 h,
1700 h, 1930 h).
CAR (slope); circadian
profile (AUCG, intra-
individual standard
deviation).
Momentary fatigue
(‘‘I feel tired’’;
1—5).
Steeper (more positive)
responses to waking
associated with higher
levels of fatigue.
Negative correlation
between cortisol at T0
and fatigue level at any
point in the day.
All other tests not
significant.
7
Gold et al.
(2011)
Cross-sectional Multiple sclerosis
(relapsing-
remitting), 44
(100), 35.8 years
(0.7).
Days: 2c; assessments: 9
(T0, T15, T30, T45, T60,
1100 h, 1500 h, 2000 h,
2200).
CAR (AUCG); circadian
profile (AUCG).
Modified Fatigue
Impact Scale;
Fatigue Severity
Scale.
No evidence of a
relationship between any
markers of basal CSA and
level of fatigue.
7
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Table 3 (Continued )
Study Design Sample
population, N (%
female), mean age
(SD)a
Saliva sampling protocol Basal cortisol
computations
Fatigue measure Main findings Quality
scoreb
(16)
McLean
et al. (2005)
Cross-sectional Fibromyalgia, 16
(100), 43 years (9).
Days: 2; assessments: 5
(T0, T60, 5 h after
waking, late afternoon
(1500—1600 h), 30 min
before bed).
Fixed time points only. Momentary fatigue
(wording
unavailable; 1—
100).
No evidence of a
relationship between
momentary fatigue and
concurrent levels of
circulating cortisol at any
time point.
14
Sudhaus
et al. (2009)
Cross-sectional Acute and chronic
lower back pain
(ALBP; CLBP), two
groups: ALBP = 19
(63), 39.8 years
(12.3); CLBP = 24
(71) 38.3 years
(11.4).
Days: 2; assessments: 5
(T0, T15, T30, T45, T60).
CAR (AUCG). General Fatigue
Scale of the Multi-
dimensional
Fatigue Inventory.
CAR AUCG correlated with
fatigue in positive
direction in ALBP and
negative direction in
CLBP.
Within the CLBP group,
highly fatigued
individuals had blunted
CAR compared to those
with low fatigue.
10
a N, sex, age, and cortisol computations reported or used in relevant analyses (patient group in all cases).
b See quality scale items and respective scores in supplementary material for further information.
c A third day was post-administration of dexamethasone.
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Table 4 Characteristics of general population studies.
Study Design Sample population, N
(% female); mean age
(SD)
Saliva sampling
protocol
Basal cortisol
computations
Fatigue measure Main findings Quality
scorea
(16)
Eek et al.
(2012)
Cross-sectional Workers, 581 (61);
46.3 years (10.7).
Days: 1; assessments:
3 (T0, T30, 2100 h).
CAR (morning peak, %
increase between T0 and
T30, mean of T0 and T30);
circadian profile (mean
cortisol, evening minus
morning peak).
Fixed time points.
Swedish
Occupational
Fatigue Inventory.
% increase in CAR
positively associated with
lack of energy, lack of
motivation, and physical
exertion subscales of the
SOFI-20. Physical
exertion also negatively
associated with T0.
Associations stronger in
women than in men (all
associations mentioned
above not significant in
male-only analyses).
5
Kumari
et al. (2009)
Cross-sectional and
longitudinal: (1)
Phase 6 (P6; 2001);
(2) Phase 7 (P7;
2003—2004); (3)
Phase 8 (P8; 2006)
Whitehall II cohort,
4299,
‘‘Fatigued’’ = (22.3%
female); 61.4 years
(SD not given); ‘‘Not
fatigued’’ = (34.2%
female); 59.8 years
(SD not given).
Days: 1; assessments:
6 (T0, T30, T2.5 h,
T8 h, T12 h, bedtime).
Measured at P7 only.
CAR (T30 minus T0);
circadian profile (slope,
using all samples except
T30); fixed time points.
Vitality subscale of
SF-36 (cut-
off = 50).
Fatigue measured
at all phases.
Longitudinal (P6/P7):
fatigue at P6 not
predictive of any cortisol
measures at P7.
Cross-sectional (P7): no
difference in CAR
between fatigued and not
fatigued groups. T0, T30,
and slope all lower or
flatter in fatigued group
(but T0 cortisol
association accounted for
by other health
measures). Bedtime
cortisol higher in fatigued
group.
Longitudinal (P7/P8):
those with flatter slopes
at P7 more likely to
report persistent fatigue
across both P7 and P8, or
new fatigue in P8 for
those without fatigue at
P7.
9
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2416 D.J.H. Powell et al.One CFS study without a control group measured levels of
fatigue within the sample (Torres-Harding et al., 2008). The
study found no relationship between fatigue and either the
daily mean cortisol computation or the DCS. However, using a
classification approach, a physician categorized participant
circadian cortisol profiles as ‘‘normal’’ or ‘‘abnormal’’ (based
on ‘‘expected’’ ranges of cortisol profiles), and found that
‘‘abnormal’’ profiles were associated with higher levels of
fatigue severity. ‘‘Abnormal’’ profiles did not reflect a spe-
cific type of cortisol growth trend but did contain at least one
of the following features: (1) ‘‘cortisol patterns or results
exhibiting divergent peak times’’; (2) ‘‘decreases in cortisol
level followed by sudden increases’’; or (3) ‘‘general
attenuation of cortisol pattern’’ (Torres-Harding et al.,
2008, p. 166). The validity of this classification is unknown,
and has not been replicated to the best of our knowledge.
3.4. Fatigue and cortisol secretory activity in
other clinical groups
Table 3 shows the characteristics of each of the studies incor-
porating clinical populations. Previous evidence has suggested
a high prevalence of fatigue in each of the conditions repre-
sented here: multiple sclerosis (Lerdal et al., 2003); rheuma-
toid arthritis (Belza, 1995); fibromyalgia (White et al., 2000);
chronic lower back pain (Fishbain et al., 2004); traumatic brain
injury (Oullet and Morin, 2006); and HIV (Breitbart et al.,
1998). Most studies recruited healthy control groups, but
the relationship between CSA and fatigue within the control
group was not reported in any study.
The CAR was examined in three of the seven studies
(Dekkers et al., 2000; Sudhaus et al., 2009; Gold et al.,
2011). All of these studies computed CAR AUCG, while one
also operationalized individual CAR dynamic responses as
regression slope parameters (Dekkers et al., 2000). Only
one study found a relationship between fatigue level and
AUCG (Sudhaus et al., 2009). In this study, the chronic lower
back pain group had associations between greater fatigue
and attenuated CAR output, but the acute lower back pain
group showed the opposite: greater fatigue was associated
with elevated CAR output. A median split on the Multidimen-
sional Fatigue Inventory (MFI; Smets et al., 1995) showed
there were CSA differences between high and low fatigue
only within the chronic pain group, with an attenuated CAR
AUCG in those categorized as high fatigue compared to low
fatigue. In the remaining two studies, CAR AUCG was not
associated with fatigue level (Dekkers et al., 2000; Gold
et al., 2011).
As mentioned, the CAR dynamic response was assessed in
only one study (people with rheumatoid arthritis). Higher
slope parameters (steeper cortisol responses to awakening)
were associated with greater levels of daytime fatigue, but
not daytime fatigue variability (Dekkers et al., 2000).
Momentary fatigue assessments were incorporated in this
study to compute these variables. The authors also per-
formed time-lagged associations between fixed momentary
assessments, finding correlations of T0 cortisol with fatigue
at any assessment during the day at around r = .35, with
successive cortisol assessments up until 1000 h becoming
less negatively correlated with fatigue. These time-lagged
analyses imply that increased CSA within the first hour of
awakening, particularly precisely upon awakening, may be
Figure 2 Forest plots for (i) CAR estimated total cortisol output; (ii) CAR estimated dynamic response; and circadian profile total
cortisol output in CFS (iii) with, and (iv) without Papadopoulos et al. (2009) paper.
Unstimulated cortisol secretory activity and its relationship with fatigue 2417related to how fatigue is experienced throughout the rest of
the day in rheumatoid arthritis.
Five of the seven studies examined at least one facet of
the circadian cortisol profile (Dekkers et al., 2000; Bower
et al., 2005; McLean et al., 2005; Bay and Xie, 2009; Gold
et al., 2011) and one study characterized circadian cortisol
profiles into different ‘‘cortisol trends’’ using visual categor-
izations after having problems having saliva samples from
their HIV population analyzed (Barroso et al., 2006). No study
found any relationship between total estimated cortisol out-
put over the day and fatigue. Bower et al. (2005) found no
differences in cortisol AUCG or mean cortisol between those
categorized as fatigued (score < 50) or not fatigued
(score > 70) by the energy/fatigue subscale of the RAND
SF-36 (Hays et al., 1993). Gold et al. (2011) found that
cortisol AUCG was not a significant predictor of cross-sec-
tional fatigue. Bay and Xie (2009) also observed that cortisolAUCG did not make a significant contribution to a statistical
model of fatigue.
In terms of CSA daily variability, Bower et al. (2005)
reported that higher levels of fatigue severity were asso-
ciated with a flatter DCS. Those within the fatigued group had
a flatter DCS than those who were not fatigued, with approxi-
mately 25% of between-subject DCS variation accounted for
by fatigue group. Dekkers et al. (2000) found that the intra-
individual standard deviation of cortisol (‘‘daytime cortisol
variability’’) was not associated with level of fatigue.
The only study in an HIV population had participants’
saliva samples refused by the planned analysis laboratory
(Barroso et al., 2006). The alternative laboratory required
samples be diluted 16 times, which led the authors to render
only primitive analyses appropriate. Cortisol profiles were
categorized into different trends: (1) ‘‘normal downward
trend’’; (2) ‘‘afternoon fall’’; (3) ‘‘afternoon peak’’; (4)
2418 D.J.H. Powell et al.‘‘upward trend’’. Although no statistical testing was con-
ducted between groups, it was apparent that those with a
‘‘normal downward trend’’ had the lowest ratings of fatigue
on the Fatigue Severity Index, computed from the intensity
and consequences subscale of the HIV-Related Fatigue Scale
(Barroso and Lynn, 2002).
Two studies looked at associations between fixed-occasion
salivary cortisol assessments and momentary fatigue (Dek-
kers et al., 2000; McLean et al., 2005). Neither showed any
associations between cortisol and concurrent fatigue,
although lagged associations, as detailed previously, were
apparent in the rheumatoid arthritis study (Dekkers et al.,
2000). Bower et al. (2005) found that between ‘‘fatigued’’
and ‘‘not fatigued’’ participants, there were differences in
salivary cortisol levels only in the evening, with cortisol levels
marginally higher in the fatigued group at 1700 h and reached
significance at 2200 h.
3.5. Fatigue and cortisol secretory activity in
nonclinical populations
Three studies examined the relationship between fatigue and
CSA in nonclinical populations (Lindeberg et al., 2008; Kumari
et al., 2009; Eek et al., 2012). Table 4 depicts study char-
acteristics for each. Two studies examined facets of the CAR
in relation to fatigue (Kumari et al., 2009; Eek et al., 2012).
Eek et al. (2012) computed mean cortisol between T0 and T30
as an estimation of CAR output, and computed a percentage
increase from T0 to T30 as a marker of the dynamic cortisol
response to waking. The study found no correlation between
CAR output and fatigue on five subscales (lack of energy;
physical exertion; physical discomfort; lack of motivation;
sleepiness) of the Swedish Occupational Fatigue Inventory
(SOFI; A˚hsberg et al., 1997). However, positive associations
between the CAR dynamic response and three of the SOFI
subscales (lack of energy; physical exertion; lack of motiva-
tion) were found, but in subsequent analyses these were
found to be present in female participants only. Conversely,
Kumari et al. (2009) operationalized the CAR dynamic
response by calculating peak (T30) minus nadir (T0), and
categorized participants into two groups based on a cut-off of
50 on the vitality subscale of the SF-36 (Ware and Sher-
bourne, 1992). No differences were found for CAR peak minus
nadir between the fatigued and not fatigued groups.
In the third study, salivary assessments were made at T0,
T30, and 2100 h (Lindeberg et al., 2008). Participants were
split into two groups based on a cut-off of 16 on the vitality
subscale of the SF-36. There were no differences in daily
mean CSA between groups, but the more fatigued group did
have significantly lower peak minus nadir values (flatter
cortisol profiles). In addition, the study found a negative
correlation between vitality score and peak minus nadir
values such that they became smaller, and cortisol profiles
flatter, with increasing fatigue (vitality scores were inverted
such that higher scores indicated more fatigue). Eek et al.
(2012) did not find any associations between fatigue and
mean cortisol level or peak minus nadir cortisol values.
However, Kumari et al. (2009) found the DCS was flatter in
the more fatigued group.
All three studies examined associations between fatigue
and salivary cortisol at fixed assessment time points (Linde-
berg et al., 2008; Kumari et al., 2009; Eek et al., 2012).Kumari et al. (2009) observed lower cortisol levels in the
more fatigued group at T0 and T30, and higher cortisol levels
at bedtime, with no differences for any of the fixed afternoon
assessments (T2.5 h; T8 h; T12 h). Eek et al. (2012) found a
negative correlation between the physical exertion subscale
of the SOFI scale and cortisol at T0 (in females only), but no
associations with any other subscale or at any other time
point. No differences were found between groups at any
occasion (T0, T30, nor 2100 h) in the study by Lindeberg
et al. (2008).
Only one study included in this review had a longitudinal
facet to its design (Kumari et al., 2009), and was a large
epidemiological study that recruited from the Whitehall II
cohort (see Marmot and Brunner, 2005) categorizing each
individual as fatigued or not fatigued, as already outlined, at
Phase 6 (2001), Phase 7 (2003/2004), and Phase 8 (2006).
Salivary cortisol assessments were made only at Phase 7. The
study revealed no association between Phase 6 levels of
fatigue and Phase 7 CAR peak minus nadir or slope parameter.
As has been stated, cross-sectional associations at Phase 7
were apparent, but the between-group differences for T0
cortisol disappeared once health measures were included in
the model. A flatter DCS at Phase 7 was associated with
persistent fatigue through Phases 7 and 8, as well as pre-
dictive of the onset of new fatigue at Phase 8.
4. Discussion
In this review, we included 19 studies published before June
2012 which examined the relationship between fatigue
experience and different markers of unstimulated (basal)
CSA in everyday life, using salivary cortisol ambulatory
assessments. We found an attenuation of cortisol diurnal
variability to be important in relation to fatigue in most
constituent studies. Measures of total cortisol output, which
discard information about diurnal variability (Adam and
Kumari, 2009), were rarely associated with fatigue in those
studies reviewed. These findings were supported by three
meta-analyses of CFS case—control studies, and by a narra-
tive synthesis of remaining clinical and nonclinical studies;
although conclusions were less clear in the non-CFS clinical
subpopulation.
4.1. Chronic fatigue syndrome
Evidence from eight case—control studies and one case-only
study indicated decreased within-person CAR and circadian
cortisol variation within CFS. An attenuation of diurnal varia-
bility concurs with the most recent review of endocrine
dysfunction in CFS (Papadopoulos and Cleare, 2012). How-
ever, the present review differs in suggesting that CSA mar-
kers that neglect cortisol variability, such AUCG, have limited
relevance to CFS; published reviews have thus far proposed
at least modest reductions in total cortisol output in CFS
(Cleare, 2003; Tak et al., 2011; Papadopoulos and Cleare,
2012).
A lack of qualifying studies prevents overly-robust con-
clusions being drawn but, taken together with the narrative
synthesis, these observations would seem consistent and
could inform the sorts of cortisol markers computed in future
empirical studies in CFS. The research area requires more
Unstimulated cortisol secretory activity and its relationship with fatigue 2419studies that incorporate prudent steps to maximizing parti-
cipant adherence to study designs to fully validate these
findings, as this is a particular weakness in those studies
reviewed here. Consensus on how best to operationalize CSA
has not yet been reached. Studies continue to report various
models of cortisol activity from constituent assessments, as
was demonstrated by two of the nonclinical studies which
had the same one-day salivary cortisol assessment design (T0;
T30; 2100 h). Despite both wanting to test associations
between fatigue and cortisol levels, each computed different
markers of CSA and came to opposing conclusions (Lindeberg
et al., 2008; Eek et al., 2012). The heterogeneity of CSA
measurement is not a criticism exclusive to CFS research, and
is apparent in other populations and, indeed, outside of the
sphere of fatigue research.
Childhood trauma may contribute to the etiology of CFS.
One study has identified childhood maltreatment as a risk
factor for CFS, and this relationship may be mediated by HPA
axis activity (Heim et al., 2009). Indeed, Heim et al. found
only those with CFS who had experienced childhood trauma
had an attenuated CAR compared to controls.
Finally, latent class analysis performed in a study of
individuals with CFS has identified up to five subgroups in
CFS, indicating that CFS is likely to be an umbrella term (Cella
et al., 2011). Earlier work by Jason et al. (2005) argued that
not employing subtypes in CFS research may be contributing
to general inconsistencies in findings within this population.
Future studies of salivary cortisol in CFS may benefit from
performing subgroup analyses based upon variables such as
depression, sleep quality, gender, and pain sensitivity.
4.2. Other clinical and nonclinical groups
AUCGmeasures were associated with fatigue in only the study
of CSA in lower back pain (Sudhaus et al., 2009), finding
associations in alternate directions depending on having
chronic (negative association) or acute (positive association)
lower back pain (Sudhaus et al., 2009). The authors specu-
lated upon reasons for this differential association: (1) when
fatigue accompanies pain, daily activities become more
stressful and there is increased CSA in acute pain via the
HPA axis stress response and (2) when this stress evolves to
become more chronic, this reflects in the HPA axis dysfunc-
tion (hypocortisolism) that was observed in the chronic lower
back pain group.
Contrary to the apparent trend in CFS studies, two studies
found larger increases upon awakening were associated with
greater fatigue (Dekkers et al., 2000; Eek et al., 2012). In
rheumatoid arthritis, Dekkers et al. (2000) argued that this
potentially reflected an ‘‘adaptive response of the HPA sys-
tem’’ to the fatigue experienced by elevating morning cor-
tisol levels to facilitate higher energy availability (Dekkers
et al., 2000, p. 367). Eek et al. (2012) found a similar
relationship with fatigue in a nonclinical population, but
secondary analyses revealed this to exist only in women.
No association between the awakening response and fatigue
level was found in a similar analysis with a different non-
clinical population (Kumari et al., 2009).
There was evidence of reduced CSA diurnal variability in
fatigued individuals in cross-sectional analyses with noncli-
nical populations. The one longitudinal study we included
indicated that fatigue severity did not predict CSA 2—3 yearslater, but that some facets of CSA (flattened diurnal slope and
low waking cortisol) were predictive of concurrent fatigue,
and persistent or new fatigue 2—3 years later (Kumari et al.,
2009). These findings suggest that changes in basal CSA may
occur prior to the onset of (or early in the process of devel-
oping) fatigue; a position which would appear at odds with
the argument made in the rheumatoid arthritis study that the
HPA axis may become more active in order to facilitate
increased energy metabolism when experiencing fatigue
(Dekkers et al., 2000).
4.3. Relevant salivary cortisol markers in fatigue
research
In relation to fatigue experience, the relative importance of
within-day cortisol variability compared to estimations of
total cortisol output was apparent across all populations. A
significant association between fatigue and total cortisol
output was only apparent within an outlying study in CFS
(Papadopoulos et al., 2009), suggesting that this facet of CSA
is not relevant to everyday fatigue experience: chronic or
otherwise. In a review of psychosocial factors and the CAR, it
was determined that AUCI, rather than AUCG, likely repre-
sents a ‘‘more appropriate measure for assessing HPA activa-
tion following waking in relation to psychosocial factors’’
(Chida and Steptoe, 2009, p. 275). Further, estimates of total
cortisol output may be less important than measures of
circadian rhythm or variability as outcomes as these latter
types may be prominent indicators of regulatory competence
(Sephton and Spiegel, 2003). Taken together, this suggests
future studies in this field should observe at least one marker
of CSA variability, rather than exclusively make comparisons
of fixed occasion cortisol levels or estimates of total cortisol
output.
In terms of causality, it was not possible to draw firm
conclusions due to the lack of longitudinal ambulatory studies
that have been conducted thus far. It would seem from the one
study available that a flattened DCS may predict future fatigue
(Kumari et al., 2009), which complements evidence that
cortisol replacement therapy can reduce short-term fatigue
in CFS (McKenzie et al., 1998; Cleare et al., 1999). However,
there have been suggestions in previous reviews that HPA axis
activity (or dysfunction) may not be at the core of CFS, but
instead occur as a result of certain behavioral changes asso-
ciated with the illness (Cleare, 2004). Inferences from two
studies (Dekkers et al., 2000; Sudhaus et al., 2009), where CSA
variability was actually increased in relation to fatigue,
implied that fatigue may precipitate an adaptive or maladap-
tive alteration in HPA axis activity. It is not yet possible to
discern with any certainty whether specific characteristics of
CSA may trigger fatigue experience, or vice versa.
4.4. Limitations
We acknowledge several limitations of our review. A lack of
published studies, incomplete reporting, and heterogeneous
CSA measures all contributed to a small number of studies
included in each meta-analysis. Each study also contained
relatively few participants so, for both these reasons, inter-
pretations should be taken with caution. There are now a
plethora of different markers of CSA that can be computed
2420 D.J.H. Powell et al.from constituent assessments and reported, and despite
some efforts to suggest reporting consensus (for example,
Clow et al., 2004) the variety of approaches to analysis create
difficulties in making between-study comparisons in reviews
such as we report here. Some studies chose to examine only
fixed occasion assessments, rather than compute other
potentially more informative markers of CSA such as a variant
of the AUC or DCS. The issue of consensus in the reporting of
cortisol markers is something that should be addressed in HPA
axis research with a degree of urgency (Clow et al., 2010).
Psychiatric comorbidity was also present within some
study samples, which is particularly important within CFS
where a recent study has reported comorbidities of depres-
sion and/or anxiety disorders in around half of CFS patients
(Cella et al., 2013), and previous reports of psychiatric
comorbidities have been as high as 75% (Wessely et al.,
1996). Salivary cortisol may present at higher levels in
depressed individuals than those without depression (Knorr
et al., 2010), and Papadopoulos et al. (2009) felt that latent
mild or moderate depression with their CFS sample may have
contributed toward their unexpected outlying results. Future
research should focus on longitudinal designs, where possi-
ble, as there is a paucity of this type of evidence available
and may contribute to understanding the direction of caus-
ality between fatigue and CSA.
It is also important to note that the bidirectional relation-
ship between the immune system and the HPA axis has not
been considered within this review. It is likely that variations
in immune activity will be relevant to the experience of
fatigue in all populations, whether that be directly or indir-
ectly via changes in HPA axis function (Bansal et al., 2012).
4.5. Conclusions
In conclusion, this review suggests that attenuation of CSA
variability, in terms of dynamic responses to waking and
variations in circadian activity, is the most relevant facet
of CSA within fatigued individuals across all populations. The
review was unable to unequivocally support the hypocorti-
solism hypothesis in CFS, although it would seem that smaller
increases in cortisol after awakening are apparent within this
clinical group. Longitudinal evidence was minimal, and
therefore no robust conclusions could be drawn regarding
causality in the association of fatigue experience with unsti-
mulated CSA.
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